Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $10.00 target price on the stock.

Several other equities analysts also recently commented on the company. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. D. Boral Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Immunic in a research note on Wednesday. William Blair initiated coverage on shares of Immunic in a report on Tuesday, March 25th. They issued an “outperform” rating on the stock. Finally, B. Riley restated a “buy” rating and set a $6.00 price target on shares of Immunic in a report on Wednesday, April 16th. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $13.20.

Immunic Stock Performance

IMUX opened at $1.15 on Thursday. The company has a market cap of $110.19 million, a PE ratio of -0.93 and a beta of 1.91. The stock has a 50-day moving average of $1.08 and a 200-day moving average of $1.11. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Immunic by 90.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after buying an additional 96,894 shares during the last quarter. Millennium Management LLC raised its holdings in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares in the last quarter. Focus Partners Wealth raised its holdings in Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after acquiring an additional 23,610 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the period. Finally, 683 Capital Management LLC increased its position in shares of Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares during the period. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.